Arcato Laboratories, developer of OraWax™, a revolutionary new treatment for the discomfort caused by orthodontic braces, has been selected to demonstrate breakthrough life science innovation at the CED Life Science Conference, March 1-2 in Raleigh.
“The technology platform of Arcato Laboratories is based upon a patented method of delivering a local anesthetic to oral mucosal membranes over a sustained period of time,” said Meldrum. “The Arcato technology platform has many applications for other types of pain relief, but the OraWax™ product alone has an estimated market of about $400 million per year,” he added.
“We received over 100 applications from across the state, validating that North Carolina remains a hotbed for life science innovation,” said Joan Siefert Rose, President and CEO of CED. “The CED Life Science Conference will showcase companies beyond traditional life science advancement, from crafting devices used by eye surgeons that will improve both the surgeon and patient experience to addressing oncology, genetic disease, and more with genome editing. These are the people right here in our state that are discovering, developing, and creating in order to improve lives in the U.S. and around the world.”
Arcato is currently raising $1 million in a Series B round of financing, to complete 510(k) FDA regulatory clearance for OraWax™, and launch the product in the United States.